Programmed cell death does not cause the thoracoabdominal schisis seen in the FlnA+Fmn2 double null mice. by Gewei Lian (523268)

“…<p>Fluorescent photomicrographs show decreased rates of programmed cell death (fluorescein) between WT vs null FlnA, and WT vs null FlnA+Fmn2 cortex within the mouse sternum (WT vs null FlnA ** = p < 0.00012, Wt vs null FlnA+Fmn2 ** = p < 0.0004, null FlnA vs null FlnA+Fmn2 * = p < 0.05). …”

Effect of dilution and DMSO concentration on the interaction of NF-κB/DNA complex with the inhibitors. by Rodrigo Villagomez (685829)

The relation of BMI Z-scores at one year and the variability of blood phenylalanine levels in the first year of life for infants with PKU and MHP—Carriers of the rs113883650 varian... by Miroslaw Bik-Multanowski (5700350)

Morpholino-Mediated Increase in Soluble Flt-1 Expression Results in Decreased Ocular and Tumor Neovascularization by Leah A. Owen (178086)

MiR-20a overexpression decreases LIMK1 protein expression in thyroid cancer cell lines. by Yin Xiong (342546)

Persistent organic pollutant exposures are associated with liver toxicity and decreased albumin in a highly exposed human cohort by Matthew Cave (9148916)

Decreased Platelet Count in Patients Receiving Continuous Veno-Venous Hemofiltration: A Single-Center Retrospective Study by Buyun Wu (563610)

“…<div><p>Background</p><p>A decreased platelet count may occur and portend a worse outcome in patients receiving continuous renal replacement therapy (CRRT). …”

Expression of Aβ42 decreases K_v4 protein and currents in the intact brain. by Yong Ping (233004)

Discovery of the Triazolo[1,5‑<i>a</i>]Pyrimidine-Based Derivative WS-898 as a Highly Efficacious and Orally Bioavailable ABCB1 Inhibitor Capable of Overcoming Multidrug Resistance... by Shuai Wang (109515)

Subjects:

Discovery of the Triazolo[1,5‑<i>a</i>]Pyrimidine-Based Derivative WS-898 as a Highly Efficacious and Orally Bioavailable ABCB1 Inhibitor Capable of Overcoming Multidrug Resistance... by Shuai Wang (109515)

Subjects:

Compound CID 9998128 Is a Potential Multitarget Drug for Alzheimer’s Disease by Nguyen Quoc Thai (5348798)

“…Moreover, the compound dose-dependently decreases β-site amyloid precursor protein cleaving enzyme (BACE-1) activity with EC₅₀ value in micromolar range. …”

Compound CID 9998128 Is a Potential Multitarget Drug for Alzheimer’s Disease by Nguyen Quoc Thai (5348798)

“…Moreover, the compound dose-dependently decreases β-site amyloid precursor protein cleaving enzyme (BACE-1) activity with EC₅₀ value in micromolar range. …”

Supplementary Material for: Use of the Myocardial Performance Index in Decreased Fetal Movement Assessment: A Case-Control Study by Ho D. (4108837)

“…<p><b><i>Objectives:</i></b> To determine whether there are any fetal cardiac function changes, as measured by the myocardial performance index (MPI), in pregnancies complicated by decreased fetal movement (DFM). <b><i>Methods:</i></b> We performed a prospective cross-sectional case-control study of 50 DFM and 50 uncomplicated third-trimester pregnancies matched within 2 gestational weeks. …”

Group mean values and standard deviation of the normalized maximal torques (NMT) in the knee extensors (KE), the hip abductors (AB), and the hip adductors (AD) as well as for the r... by Franziska Daun (6433328)

Prevalence of antimicrobial resistance to folate pathway inhibitors exhibits a decreasing linear trend from 2002–2016. by Kelly E. Davidson (5464472)

Methotrexate susceptibility of <i>L</i>. <i>major</i> Friedlin mutants derived from a Mut-seq screen. by Sophia Bigot (16469992)

M344 decreases orthotopic pancreatic tumor growth when used as a treatment alone or in combination with gemcitabine. by Shelby M. Knoche (13833807)

Expected and delivered services to local communities by the local mining industry. by Mothusi Boihang (13149705)

Drive dynamics for split^<50cM <i>ClvR</i>s with different genetic linkage and migration rates. by Georg Oberhofer (3401438)

The process of selecting participants. by Na Li (6550)

“…Chemotherapy was found to be protective factor for OS (HR = 0.33, 95%CI: 0.30–0.37)/CSS (HR = 0.44, 95%CI: 0.39–0.50) of ovarian cancer patients, while not receiving surgery remained a risk factor. …”